About Us

How to Cross "One-Step Distance" in Innovative Drugs

time:01/22/2015 page views: resource:BioBAY
 For Chinese pharmaceutical companies, the ultimate goal for developing new drugs is to see the clinical values, no matter which approach is adopted to complete the change of the role in innovations. However, such a "step" is a distance to success or failure for the companies, i.e. the winner successfully going across the distance shall enter the "paradise" with tremendous benefits from patented innovative drugs, while the loser shall obtain nothing from years of innovations with high investment.
What the market expects are innovative drugs showing the good efficacy, less side effects and good compliance in clinical trials. How to interpret the new CFDA regulations and the future trends? How to avoid the fatal mistakes commonly seen in IND application and clinical trial design? How to efficiently communicate with CFDA? Such issues are very important for the reasonable planning of the clinical research and registration of innovative drugs. We are very pleased to invite Dr. Zhang Dan, CEO of Fountain Medical Development Ltd. (FMD), to share the experience in clinical R&D and registration of new drugs with companies in the Park.
Time: 13:30-17:00 pm, January 9
Venue: BioCAFÉ, 1/F, North Block, Building A1, BioBAY


Any interested party may contact Ms. Zhan Xin, Industrial Services, BioBAY, at 0512-62956666-6018,

Dr. Dan Zhang received his pre-med training from Peking University from 1981 and received his M.D. from Peking Union Medical College in 1989. He continued his study at the Harvard and the Wharton Business School of the University of Pennsylvania, where he obtained his MPH and master's degree in healthcare management. He was the recipient of US Federal Government Prize for Medical Service Research in 1993, and served as the secretary general of Expert Fellowship for "1000-Plan".
Dr. Dan Zhang was chairman of Greater China Region, vice president and member of Executive Operation Committee of Quintiles Transnational Corp., the world largest drug CRO company; and then he was the head of clinical development for North American market and global safety assessment at Sigma-Tau Research Inc., the largest drug-maker in Italy. He obtained 6 clinical approvals from FDA and 1 drug marketing certificate during his service in such companies, in which 1 anti-cancer drug was acquired by Nowartis, and 1 anti-heart failure drug acquired by Debiopharm. He is now chairman and CEO of Fountain Medical Development Ltd.

About FMD

Fountain Medical Development Ltd. (FMD) is a contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services for multinational clients conducting clinical research in China. The management team of Fountain has decades of combined experience working with the world's leading CRO's and drug developers. In the Chinese CRO market, we fill the void of a service provider that balances high quality with moderate cost. Our extensive global experience in multiple therapeutic areas is unmatched by other local CRO's, and our lower operational cost allows us to pass significant savings on to our clients.